A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
Researchers found leukemias trending higher as the ‘baby boomer’ generation ages. Interestingly, incidence of all cancers was not correlated with the increase in older Americans.
This trial employed chemotherapy-free induction therapy followed by assessment of MRD status to triage patients for subsequent therapy with or without chemotherapy.
The combination of the antiproliferative agent ibrutinib, with the proapoptotic agent venetoclax, may target the dual pathophysiology characteristic of CLL.
A retrospective study sought to determine the risk of solid-tumor second malignancy associated with an infectious etiology for patients with certain lymphomas or leukemias.
Patients with CLL who had symptomatic bronchial involvement had a significantly higher proportion of anomalies in small airways and peripheral bronchi.
Chimeric antigen receptor T-cell therapy “liso-cel” was deemed safe and clinically active in chronic lymphocytic leukemia and small lymphocytic leukemia.
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
